Design of Trials, Meta-analyses and observational studies

A single clinical trial in prostate cancer has already tested multiple treatments at once, dropping ineffective ones and adding new ones as it runs—and now the same flexible design is being adapted for tuberculosis, bone cancer, and melanoma. This matters because the traditional way of testing new drugs—one treatment, one trial, one disease at a time—is too slow. There are far more promising new agents and biomarkers than the current system can evaluate efficiently. The MAMS (multi-arm, multi-stage) design lets researchers test several treatments in parallel, stop the ones that fail early, and add new ones without restarting the trial. The FOCUS4 trial in colorectal cancer goes further by linking treatment evaluation to biomarker testing in a single framework, so doctors can identify which patients are most likely to benefit from which drug. If these designs become standard, clinical trials could run faster and cheaper, delivering effective treatments to patients years earlier. The approach is already being considered for pancreatic and upper gastrointestinal cancers. This is not fundamental science—it is a practical overhaul of how clinical evidence is generated, with immediate implications for trial infrastructure and regulatory approval pathways.